3
Announcements
Trials
Browse
Landscape
Status
Withdrawn
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Observational
2
Sponsor
Cancer Type
Gastrointestinal
5
Breast
3
Head & Neck
2
Genitourinary
2
Lymphoid
1
Conditions
Prostatic Neoplasms
1
Carcinoma, Renal Cell
1
Adenocarcinoma
1
Interventions
pembrolizumab
182
Magnetic Resonance Spectroscopy
161
Specimen Handling
134
enzalutamide
125
Nivolumab
118
Gemcitabine
96
Docetaxel
92
Radiosurgery
91
Prednisone
81
Androgen Antagonists
81
Abiraterone Acetate
79
Radiotherapy
75
apalutamide
66
Cisplatin
65
darolutamide
62
Ipilimumab
61
Biopsy
61
abiraterone
57
cabozantinib
55
Carboplatin
55
Leuprolide
52
enfortumab vedotin
50
Radiation
47
Pluvicto
45
Standard of Care
44
atezolizumab
41
Surveys and Questionnaires
38
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
37
X-Rays
37
avelumab
35
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Radiofrequency Ablation
×
Genitourinary
×
1 year
×
Clear all
NCT07237399
2026-05-13
TA-P-OLIM
University Hospital, Ghent
Withdrawn
NCT07465458
2026-03-16
RASROP-003
Humanitas Hospital, Italy
Not yet recruiting
226 enrolled